Borregaard & Partners Invest EUR 6.2M In Kaffe Bueno

Strategic Co-Investment for Bioscience Growth In Kaffe Bueno

Norwegian company Borregaard, alongside the European Innovation Council Fund and a consortium of public and private investors, has announced a significant investment in Kaffe Bueno ApS, a Danish bioscience firm specializing in coffee by-product applications. The total capital infusion of EUR 6.2 million through a direct offering of new shares will see Borregaard securing a 12% stake in Kaffe Bueno with an initial investment of EUR 3 million.

Enhanced Potential Through Warrants

The agreement also includes warrants for Borregaard, allowing it to potentially increase its stake to 34% by 31 January 2026. This conditional increase would involve an additional EUR 9.25 million investment, reflecting Borregaard’s long-term commitment and belief in Kaffe Bueno’s potential.

Innovative Applications Driving Growth

Kaffe Bueno leverages innovative technology to transform coffee by-products into valuable, active, and functional ingredients. These ingredients find diverse applications across personal care, human nutrition, and agriculture. The current investment is a strategic move to enhance Kaffe Bueno’s capabilities, particularly in constructing a 500-tonne per year biorefinery in the Copenhagen area. This facility is expected to be a cornerstone in scaling production and bringing new, sustainable products to the market.

Market Expansion and Product Development

The fresh capital will aid in completing the biorefinery and enable Kaffe Bueno to introduce its first commercial volumes to the market. This development marks a significant step in Kaffe Bueno’s journey to becoming a key player in the bioscience industry. By expanding its product portfolio and enhancing production capabilities, Kaffe Bueno is set to meet the growing demand for sustainable and innovative consumer and industrial products.

Forward Outlook

This co-investment reflects a shared vision among the investors for a sustainable and innovative future in bioscience. As Kaffe Bueno progresses with its construction and product development, the industry eyes are on how this strategic funding will translate into market growth and innovation leadership. Borregaard’s potential increase in ownership underscores the strategic importance of this partnership, signaling robust confidence in Kaffe Bueno’s future and the broader bioscience sector.